Khadzhidekova V, Krusteva E, Bulanova M, Ivanov V, Benova D
Genetika. 1988 Dec;24(12):2237-42.
The mutagenicity of thaliblastine (Bulgarian potential antitumor drug) was investigated in vitro in lymphocytes from healthy donors, and in vivo in lymphocytes of oncological patients after thaliblastine administration. No increase in the rate of chromosome aberrations was noted with increasing thaliblastine concentrations in vitro and in the course of therapy in vivo. Some polyploid metaphases were found in the lymphocytes of the patients treated with thaliblastine, as a result of the statmokinetic effect of the drug. Thaliblastine exerts extraordinarily slight mutagenic effect, as compared with other cytostatics.
对thaliblastine(一种保加利亚潜在抗肿瘤药物)的致突变性进行了体外研究,采用健康供体的淋巴细胞,以及体内研究,在给肿瘤患者施用thaliblastine后检测其淋巴细胞。体外随着thaliblastine浓度增加以及体内治疗过程中,均未观察到染色体畸变率升高。在用thaliblastine治疗的患者淋巴细胞中发现了一些多倍体中期相,这是该药物的静止期动力学效应所致。与其他细胞抑制剂相比,thaliblastine的致突变作用极其轻微。